Type II endometrial carcinomas (ECs) are estrogen independent, poorly differentiated tumors that behave in an aggressive manner. As TP53 mutation and CDH1 inactivation occur in 80% of human endometrial type II carcinomas, we hypothesized that mouse uteri lacking both Further, inflammatory mediators secreted from CDH1-negative, TP53 mutant endometrial cancer cells induced normal macrophages to express inflammatory-related genes through activation of nuclear factor-κB signaling. These results indicate that absence of CDH1 and TP53 in endometrial cells initiates chronic inflammation, promotes tumor microenvironment development following the recruitment of macrophages and promotes aggressive ECs.
INTRODUCTION
Endometrial cancer is the most common malignancy of the female genital tract, affecting 452000 women and leading to approximately 8500 deaths in the United States each year. 1 Two types of endometrial carcinomas (ECs) have been distinguished, type I (T1EC) and type II (T2EC).
2 T1ECs, which account for 80% of all ECs, are associated with hyperestrogenism, have a good prognosis, exhibit atypical hyperplasia and usually develop in premenopausal and peri-menopausal women. 3, 4 T2ECs are high-grade, estrogenindependent and diagnosed mainly in postmenopausal women. Although only 15-20% of ECs belong to T2ECs, these tumors appear to be very aggressive, and 450% of patients present with recurrent disease shortly after primary treatment. [5] [6] [7] Further, o30% of the patients with T2ECs survive 5 years after initial diagnosis. 5 Therefore, a clear understanding of the mechanisms involved in tumor development of T2ECs is necessary for early stage diagnosis as well as rational design of therapies.
T2ECs are poorly differentiated, aggressive tumors. [8] [9] [10] The most common histological tumor type is serous carcinoma comprised of atypical cells that grow into papillary, glandular or solid tumors. 8, 9, 11 A number of studies have reported that TP53 mutations are associated with poor prognosis. 4, 8, 12 Inactivation of TP53 renders cells non-responsive to signals that challenge genomic integrity, thereby promoting the acquisition of novel and harmful cellular phenotypes that are characteristic of cancer cells, such as resistance to apoptosis, neoangiogenesis and enhanced proliferative and invasive potential. Approximately 80% of T2ECs harbor TP53 mutations. Although TP53 mutations are less common in T1ECs, those reported have been largely confined to high-grade tumors (grades 3 and 4). 8 In addition to TP53 mutation, inactivation of CDH1 is also a common molecular feature in T2ECs. 4, 10 CDH1 is critical in the establishment of cell polarity and maintenance of the epithelial phenotype. 13 CDH1 is often downregulated or lost during tumor progression, [14] [15] [16] [17] leading to increased tumor invasiveness and metastasis. 4, [18] [19] [20] [21] [22] Mice with either Trp53 heterozygous or homozygous deletion develop a variety of cancers, with most homozygous mice dying by 6 months due to development of widespread lymphoma, but Trp53-null mice rarely form ECs. [23] [24] [25] Pgr Cre/+ mice have been recognized as an excellent model to target genes in the uterus after birth. 26 Although conditional uterine ablation of Pten driven by Pgr-Cre results in the development of T1ECs in mice, 27 ,28 the uteri of mice lacking Trp53 alone do not exhibit any abnormal morphology by 5 months. 27 We have recently reported that conditional ablation of Cdh1 in the mouse uterus results in a disorganized cellular structure of the epithelium and ablation of endometrial glands, leading to implantation defects. 29 However, loss of Cdh1 alone in the uterus does not predispose mice to tumors. Conditional ablation of Cdh1 does not induce tumors in mammary glands [30] [31] [32] or stomach, 33 whereas loss of Cdh1 and Trp53 induces invasive lobular carcinoma in mammary glands with massive angiogenesis. 31, 32 Thus, these results indicate that single gene ablation in the uterus is not sufficient to understand the etiology of heterogeneous aggressive types of ECs.
In the present study, we generated a mouse model in which Cdh1 and Trp53 were conditionally ablated in the uterus. Ablation of Trp53 and Cdh1 accelerated endometrial neoplastic transformation and induced cell invasion and dissemination. Further, the results of the present study suggest that ablation of Cdh1 and Trp53 in the mouse uterus initiates chronic inflammation with tumor microenvironment modification, which promotes aggressive ECs.
RESULTS

Generation of mice with
Cdh1 and Trp53 ablation in the mouse uterus Because TP53 mutation and CDH1 inactivation are the two most common found molecular features in human T2ECs, 3, 4 our objective was to study the combined effect of dysfunctional uterine TRP53 and CDH1. As Cdh1-null mice show early embryonic lethality, 34, 35 we conditionally deleted both Cdh1 and Trp53 in the uterus using Pgr Cre/+ mice. Pgr Cre/+ mice were crossed with Cdh1 f/f and/or Trp53 f/f mice to provide a tissue-specific knockout of Cdh1 and/or Trp53 in Pgr-expressing cells:
(Supplementary Figure S1) . The ability of Pgr-Cre to mediate ablation of Cdh1 and Trp53 in the uterus was confirmed by CDH1 immunoreactivity and Trp53 mRNA analysis (Supplementary Figures S1b and c) . Although Cre recombinase in Pgr Cre/+ mice is active in all cell types of the uterus, ablation of both Cdh1 and Trp53 in the uterus only occurs in the epithelial cells as endogenous CDH1 is expressed only in the uterine epithelium. Although PGR is expressed in the oviduct, ovary, mammary gland and pituitary, we did not see any histological and/or functional abnormalities in other tissues lacking Cdh1 and Trp53 (data not shown).
Impact of conditional ablation of Cdh1 and Trp53 in the uterus Six different genotypes of mice (control,
were generated. Although ovarian function in all genotypes was normal, we performed ovariectomy at 6 weeks of age in order to mimic the human disease as T2ECs are estrogen independent and diagnosed mainly in postmenopausal women. Because our first screen in six different genotypes revealed that heterozygous alleles (Cdh1 (Figures 1g and h, arrows) . We also observed ascites fluid accumulation (4 of the 15 mice) starting around 10 months (Figure 1j ). Kaplan-Meier analysis revealed that the survival time of (Figure 2k ), which is an example of de-differentiation strongly associated with aggressive tumors. Because poor prognosis in T2ECs relates to a propensity for metastasis, 36 we looked at multiple sites in the mice. We observed the first signs of disseminated tumors throughout the peritoneal cavity in (Figure 2n ). Abdominal lymph nodes, especially external iliac nodes, also showed signs of metastases, which are composed of malignant cells organized in tubular structures (Figure 2o ). These results suggest that tumorigenesis in this model proceeds through the recognized morphological intermediates leading to metastasis associated with T2ECs. 8, 37 Next, to determine whether an alteration in cell proliferation is occurring in Cdh1 38 In agreement with the lack of changes in uterine gross morphology and histology, only a few cells were Ki67 positive in the uteri from control,
mice, and a significant number of Ki67-positive cells were observed in only the Cdh1 Figure S2d) . Therefore, we focused further analyses on control and 
Chronic inflammation was initiated by ablation of Trp53 and Cdh1
Recent discoveries from both clinical and experimental studies indicate that metastatic progression is an independent process from primary tumor development, and acquisition of metastatic competence can occur at an early stage of tumor progression. [39] [40] [41] [42] To identify the genetic markers for early tumor development, we performed microarray analysis using the uteri of 2-month-old mice following ablation of Cdh1 and/or Trp53. We have deposited this data in the GEO database (GSE48131). Because single ablation of either Cdh1 or Trp53 did not cause any tumor formation ( Figures 1 and 2 ), four relevant comparisons were used to identify uterine target genes that are significantly regulated by Cdh1 and/or Trp53. We identified 120 genes that were in common between comparison 3 and 4 (fold-change 42 and false discovery rate P o0.05, Supplementary Figures S4a and b) . Differentially expressed genes were classified by functional annotation using DAVID analysis 43, 44 and IPA program (Ingenuity Systems, Mountain View, CA, USA). These 120 genes were categorized into groups of inflammatory response (43) , immune cell trafficking (38) , cell-tocell signaling and interaction (43) , cellular movement (40), cellular 
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mice was performed by Kaplan-Meier analysis to assess whether ablation of Cdh1 and Trp53 is associated with short lifespan (Po0.0001). All mice were monitored for any sign of sickness. We euthanized mice with any sign of sickness or discomfort, and the day of euthanasia was recorded.
growth and proliferation (44) and tissue morphology (39) (Supplementary Figure S4c) . The results also revealed that most of the genes overlapped in multiple categories of indicated functional annotations, suggesting that ablation of Cdh1 and Trp53 causes inflammation related to aggressive and invasive cell functions. Gene groups were subjected to Gene Set Enrichment Analysis for association of misregulated genes and genetic signatures of various pathways and cellular processes described in the GO, KEGG, Biocarta and Reactome databases 45 . At a false discovery rate o 20%, 106 gene sets were significantly upregulated following loss of both Cdh1 and Trp53 (Supplementary Table S1 ). In agreement with DAVID and IPA analysis, gene sets related to cytokine signaling, inflammatory responses, cell-cell interaction and cellular morphology were significantly enriched in [46] [47] [48] and gene expression profiles of serous papillary ECs compared with normal endometrium has also been reported. 49 Our model is more similar to that described by Santin et al., 49 thus we also compared our differentially expressed genes to their published data. Cdkn2a, Claudin, Interleukin and MMP (matrix metalloproteinase) genes are significantly increased in both women afflicted with this type of ECs and our transgenic mouse model (Figures 4a and b and Santin et al. 49 ).
Inflammatory signaling within the tumor microenvironment Nuclear factor ĸB (NFĸB) and signal transducer and activator of transcription factor 3 (STAT3) are emerging as two key players involved in tumor promotion, progression and metastasis related to inflammation. [50] [51] [52] [53] IKKβ-dependent NFĸB activation has a central role in the activation of numerous pro-inflammatory cytokines in multiple cell types, including macrophages. 52, 54 Activated NFĸB promotes cell proliferation, migration and metastasis by inducing chemokines. 52, 54 Persistent STAT3 activation in malignant cells stimulates cell proliferation, survival, angiogenesis, invasion and tumor-promoting inflammation.
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3.7 ± 0. STAT3 activation within immune cells enables suppression of antitumor immunity and promotes differentiation and recruitment of myeloid cells, specifically tumor-associated macrophages (TAM). 50, 55, 56 TAMs are polarized M2 macrophages and are associated with tumor progression, as opposed to the classical macrophages of the M1 phenotype that perform key immunesurveillance and antigen-presentation functions.
57,58 Therefore, we examined phospho-IKK and phospho-STAT3, as well as known NFĸB downstream molecules (cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS)), markers for macrophages (CD68) and TAMs (CD163), a known mediator of metastasis (MMP9), as well as phospho-AKT, which is a well-known key player in T1ECs (Figures 5a and b) . 10, 37 Immunoreactivity of p-IKK, COX2, iNOS, MMP9 and p-AKT was semiquantitatively scored by H-score analysis. 59 Nuclear staining of p-STAT3 was analyzed by ImmunoRatio.
38 CD68-and CD163-positive cells were manually counted by three independent observers. Significantly increased levels of p-IKK, p-STAT3, CD68, CD163, COX2, iNOS and MMP9, but not p-AKT, were observed in Cdh1
Further, Arg1, a commonly accepted M2 marker in mice, 60, 61 was also significantly (Figure 6a ). KLE and AN3CA cells were chosen for this study due to the mutation status of TP53 in both cell lines and the absence of CDH1 in AN3CA cells (Figure 6a ). When these cells were treated with an NFκB signaling inhibitor dexamethasone (0, 0.1, 1 or 10 μM) for 24 h, IκB was dosedependently increased in AN3CA cells, but not in KLE and RK3E cells (Figure 6b ), suggesting that AN3CA cells have intact NFκB signaling, but other cells do not. S100A8 and IL1B were the only two factors from our microarray that were detectable in AN3CA The impact of Cdh1 and Trp53 ablation in the mouse uterus GR Stodden et al whether AN3CA-derived factors were able to activate NFκB signaling and stimulate inflammatory-related genes in macrophages. We observed that IκB protein was reduced in RAW264.7 cells primed in media conditioned by AN3CA cells (Figure 6d) . A dose-dependent increase in IκB was seen in RAW264.7 cells cultured with conditioned media from AN3CA cells that were treated with a dose range of dexamethasone (Figure 6e ). Further, genes identified by microarray, Il1b, Ppbp, S100a8, Cxcr2 and Cxcl5, were stimulated in RAW264.7 cells primed with conditioned media from AN3CA cells compared with RAW264.7 cells primed with RK3E conditioned media. Increased levels of these genes in RAW264.7 cells primed with AN3CA conditioned media were suppressed when AN3CA cells were treated with dexamethasone before collecting conditioned media (Figure 6f ). However, we did not see any differences in Ccl9, Csf3r, Il1rn and Clec7a in RAW264.7 cells cultured with conditioned media from vehicle or dexamethasone-treated AN3CA cells. S100a9 and Ccl17 were undetectable in RAW264.7 cells. We used Il6 as a positive control for activated NFκB signaling in RAW264.7 cells. 62 These findings indicate that NFκB signaling in EC cells results in production of inflammation-related factors that stimulate macrophages and contribute to the development of the tumor microenvironment. DISCUSSION TP53 mutation occurs in 80% of T2ECs. 3, 4 Recent genome-wide analysis has also confirmed high rates (81.6%) of somatic mutation in TP53 in serous ECs. 63 Loss of CDH1 function through genetic or epigenetic mechanisms has been implicated in the progression and metastasis of numerous malignancies. 21, [64] [65] [66] [67] [68] [69] [70] Negative or reduced expression of CDH1 is one of the features of T2ECs associated with aggressive and invasive characteristics. 10, 15, 71, 72 In our model, however, mice with single gene ablation of Trp53 or Cdh1 in the uterus did not develop ECs, indicating that inactivation of Trp53 or Cdh1 alone does not contribute to tumor initiation and progression. On the other hand, loss of Trp53 along with Cdh1 ablation induces ECs similar to human T2ECs. We report that ablation of Trp53 and Cdh1 accelerates the features of neoplastic transformation in the uterus by inducing myometrial invasion, proliferation, angiogenesis, tumor dissemination, abnormal steroid hormone receptor expression and chronic inflammation.
Histological features of Cdh1 d/d Trp53 d/d uteri exhibited papillary proliferation of small-sized cells of the surface epithelium that have very hyperchromatic nuclei similar to T2ECs pathogenesis, while ablation of Trp53 and Cdh1 did not induce welldifferentiated epithelial hyperplasia, which is one of the features of T1ECs. One of the key features between T1ECs and T2ECs is steroid hormone dependency. It is known that T2ECs are estrogen-independent disease, whereas T1ECs are an estrogendependent disease. 3, 4 Expression of ESR1 and PGR in ECs usually signifies that the tumors are well differentiated. Progestin hormone therapy has been used to slow the growth of T1ECs due to its inhibitory effects on estrogen action. However, hormone therapy does not work in T2ECs, because expression of these receptors declines in tumors that are poorly differentiated or of higher grade. 73 The present study demonstrated that ovariecto- mice is steroid hormone independent and associated with poorly differentiated phenotypes. In a previous study, we reported that single ablation of Cdh1 is associated with reduced expression of steroid hormone receptors. 74 Thus it is likely that loss of Cdh1 promotes disruption of steroid hormone receptors that contributes to steroid hormone independence in T2ECs leading to aggressive phenotypes when cells are initiated by ablation of Trp53.
Because 75 Inflammation has been established as a frequent tumor promoter through alteration of the tumor microenvironment. 76 The tumor microenvironment is expected to consist of inflammatory cells (TAM and neutrophils etc.) in addition to the cancer cells and their surrounding cells (cancer-associated fibroblasts, endothelial and mesenchymal cells). 52, 53, 77, 78 These diverse cells will communicate with each other by means of direct contact or cytokine and chemokine production and act in an autocrine and/or paracrine manners to enhance tumor progression. In the present study, we observed detectable CD68 and CD163 as well as increased levels of Arg1 in
but not in control uteri at 6 or 12 months. CD68 and CD168 are markers of macrophages and CD163 is specific to TAMs in human cancers, including ECs. 79 Arg1 is a useful M2 marker in mice. 60, 61 Thus, our results suggest that not only classically activated macrophages but also polarized M2 macrophages/TAMs, are involved in our model at this stage. When macrophage cells were cultured with conditioned media from EC cells, abundant chemokines, cytokines and enzymes from our microarray were expressed in the macrophage cells. The expression of these factors correlated with activation of NFκB signaling in cancer cells. Interestingly, these results were clearly recapitulated in macrophage cells that were primed in media conditioned by AN3CA cells, which lack CDH1 and harbor a mutation in TP53, but not by KLE cells, which have abundant CDH1 and mutated TP53. This implies that EC cells educate recruited macrophages to become TAMs by inducing the polarization of macrophages toward to the M2 phenotype through production of factors downstream of NFκB signaling in the cancer cells themselves and stimulate the production of chemokines, cytokines and enzymes to chronic inflammation by TAMs that contributes to the development of the tumor microenvironment. Although the factors derived from EC cells remain to be investigated, S100A8 and IL1B are potential candidates as both cytokines are produced by cancer cells, especially epithelial cancer cells. [80] [81] [82] We also observed complex angiogenesis and invasion in Cdh1
Angiogenesis, a critical process in tumor progression, is associated with chronic inflammation. 83, 84 TAMs are also involved in angiogenesis in cancer. 85 Although aberrant cellular invasiveness, typically accelerated by loss of CDH1, is a hallmark property of epithelial-to-mesenchymal transition (EMT), the expression of transcriptional repressors of CDH1 was not altered compared with control tissues (data not shown). Thus, any EMTlike characteristics in our model stem from direct deletion of Cdh1 and not alteration of other signaling networks that operate upstream or in conjunction with CDH1 signaling. Further, cellular invasiveness was observed in the uteri of Cdh1
Therefore, chronic inflammation caused by loss of Trp53 and Cdh1 in the uterus is the suspected cause of invasive and/or EMT-like phenotypes. In support of this, the tumor inflammatory microenvironment can facilitate the breakage of the basement membrane, a process required for the invasion and migration of tumor cells. 77 Collectively, results of the present study indicate that chronic inflammation initiated in our mouse model with Cdh1 and Trp53 ablation modifies the tumor microenvironment and promotes aggressive tumor development. Because elucidation of the molecular pathogenesis underlying T2ECs remains key to the development of novel therapeutic approaches, our mouse model provides valuable information on genetic, temporal and dynamic aspects of the tumor microenvironment in this cancer. However, activation of NFĸB signaling is not directly induced by these gene mutations in other cancers, and they exert critical oncogenic functions most likely in cancer and immune cells within the microenvironment. 85 Therefore the precise mechanism of NFκB signaling activated by the absence of TP53 and CDH1 remains to be investigated. , no.01XC2) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and the Mouse Models of Human Cancers Consortium, NIH, respectively. The uteri were collected at various time points, and uterine tissues were fixed in fresh 4% paraformaldehyde in phosphate-buffered saline at room temperature for 8-12 h and embedded in paraffin or snap-frozen in liquid nitrogen and stored at − 80°C.
MATERIALS AND METHODS
Immunohistochemical analysis
Immunolocalization of Ki67, CD31, ESR1, PGR, p-IKK, p-STAT3, CD68, CD163, COX2, iNOS, MMP9 and p-AKT was determined in cross-sections (5 μm) of paraffin-embedded uterine sections using specific primary antibodies and a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) or DyLight-conjugated secondary antibody (Jackson ImmunoResearch Laboratory, West Grove, PA, USA). Antibodies used in these analyses were: anti-CDH1 (1:120 dilution, 610181, BD Biosciences, San Jose, CA, USA), antiKi67 
Microarray and qPCR analyses
Total RNA was isolated from mouse uterus using the RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA quality was assessed, and then RNA probes were generated and hybridized to mouse WG-6 v2 Beadchip kit (Illumina, San Diego, CA, USA) in the Functional Genomics Core Facility of University of Illinois. Array data were processed in R (2.14.1) using the limma (3.10.2) BioConductor package (http://www.bioconductor.org/ packages/release/bioc/html/limma.html).
QPCR was performed following MIQE guidelines described in Supplementary Table S2 . Primers are shown in Supplementary Table S3  for mice and Supplementary Table S4 for humans.
Cell culture AN3CA, KLE, RAW 264.7 and RK3E were purchased from American Type Culture Collection (Manassas, VA, USA). All cells were authenticated by short tandem repeat analysis and passaged within 6 months of receipt.
Further, all cells were tested routinely for cell proliferation and BrdU incorporation as well as mycoplasma contamination, and they showed similar growth rate and negative mycoplasma during the experiment. All cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 200 mM glutamine and penicillin/streptomycin and grown at 37°C in a humidified 5% CO 2 incubator.
Western blotting analysis
Ten micrograms of total protein from the cell lysates were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes (Millipore Corp., Bedford, MA, USA). Membranes were blocked and incubated overnight with primary antibodies: anti-IκB (1:500 dilution, 9242, Cell Signaling Technology), anti-CDH1 (1:1000 dilution, 610181, BD Biosciences), and anti-β-actin (1:500 dilution, ab8229, Abcam). Immunoreactivity was visualized with IRDye 700 or 800 conjugated affinity-purified secondary antibodies (1:10 000 dilution, Rockland Immunochemicals, Gilbertsville, PA, USA) using the Odyssey infrared imaging system (Li-COR, Lincoln, NE, USA).
Statistical analysis
Overall survival rates were determined by Kaplan-Meier analysis, and P-value was determined by log-rank test using Prism4.0 (GraphPad, San Diego, CA, USA). All experimental data were subjected to one-way analysis of variance, and differences between individual means were tested by a Tukey's multiple-range test using Prism4.0. Tests of significance were performed using the appropriate error terms according to the expectation of the mean squares for error. A P-value of ⩽ 0.05 was considered significant. Data are presented as least-square means with s.e.m.
